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Abstract 
 
Background 
Synthetic glucocorticoids, to enhance fetal maturation, are a standard treatment when preterm birth 
before 34 gestational weeks is imminent. While morbidity- and mortality-related benefits may 
outweigh potential neurodevelopmental harms in children born preterm (<37gestational weeks), this 
may not hold true when pregnancy continues to term (≥37gestational weeks). We studied the 
association of antenatal betamethasone exposure on child mental health in preterm and term 
children. 
Methods 
We included 4,708 women and their children, born 2006-2010, from the Prediction and Prevention 
of Pre-eclampsia and Intrauterine Growth Restriction (PREDO) Study with information on both 
antenatal betamethasone treatment and child mental and behavioral disorders from the Finnish 
Hospital Discharge Register from the child’s birth to December 31st 2016. Additional follow-up 
data on mother-reported psychiatric problems and developmental milestones were available for 
2,640 children at 3.5 (SD=0.07) years-of-age. 
Results 
Of the children, 187 were born preterm (61 betamethasone-exposed) and 4,521 at term (56 
betamethasone-exposed). The prevalence of any mental and behavioral, psychological development, 
emotional and behavioral, and comorbid disorders was higher in the betamethasone-exposed, 
compared to non-exposed children [Odds Ratio 2.76 (95% Confidence Interval 1.76,4.32), 3.61 
(2.19,5.95), 3.29 (1.86,5.82), and 6.04 (3.25,11.27), respectively]. Levels of psychiatric problems 
and prevalence of failure to meet the age-appropriate development in personal-social skills were 
also higher in mother-reports of betamethasone-exposed children. These associations did not vary 
significantly between preterm and term children.  
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Conclusions 
Antenatal betamethasone exposure may be associated with mental health problems in children born 
preterm and in those who end up being born at term. 
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Introduction 
 
Fetal overexposure to maternal endogenous or synthetic glucocorticoids (sGC) may play a key role 
in offspring neurodevelopmental programming (Seckl & Meaney 2004). Fetal cortisol levels are up 
to 10 times lower than maternal levels. This is ensured by the placental glucocorticoid barrier 
enzyme, 11 beta hydroxysteroid dehydrogenase type 2 (11β HSD2), which converts 80-90% of 
active maternal cortisol to its inactive form (Seckl & Meaney 2004). While lower levels of active 
cortisol are necessary for normal brain development, fetal cortisol overexposure may harm several 
neurodevelopmental processes, and hence harm the developing brain with potential adverse 
sequelae on mental health (Damsted et al. 2011). 
 
The average prevalence of preterm delivery in developed regions in 2010 was 8.6% (Blencowe et 
al. 2012), with 7-10% of women at risk of preterm delivery being administered sGCs, such as 
betamethasone or dexamethasone (Reynolds & Seckl 2012). In high-resource settings the treatment 
carries substantial benefits for infants born before 34 weeks of gestation: incidence of respiratory 
distress syndrome has been shown to decrease by 34%, intraventricular hemorrhage by 46%, and 
neonatal mortality by 31% (March of Dimes, PMNCH & WHO 2012). Also those born late preterm 
(births between 34-36 weeks of gestation) may gain similar respiratory benefits of antenatal sGCs 
(Gyamfi-Bannerman et al. 2016). There is, thus, wide consensus that these benefits outweigh the 
potential longer-term harms sGCs may carry on individuals born preterm. Yet, prediction of 
preterm birth is uncertain, and many sGC-exposed infants end up being born at term. While some 
evidence suggests that also those born early-term (births between 37-39 weeks of gestation) after 
caesarean sections (Stutchfield 2005) may benefit from antenatal sGS in short-term  (Kamath-
Rayne et al. 2016; Saccone & Berghella 2016; The American College of Obstetricians and 
Gynecologists 2016; Sweet et al. 2017), it still remains unclear whether the short-term benefits 
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related to sCGs equally outweigh the potential longer-term harms on neurodevelopment and mental 
health in individuals born at term (Reynolds & Seckl 2012). 
 
Human evidence supporting this argument in individuals exposed to antenatal sGCs and who ended 
up being born at term is still scarce and study findings are mixed. In one randomized controlled trial 
(RCT), term-born children exposed prenatally to multiple (up to 4) courses of sGC had a higher rate 
of, and more severe, neurosensory disabilities at 5 years compared to peers exposed to a single 
course of sGC (Asztalos et al. 2014). Another RCT found no differences in behavior problems 
between 8-15-year-old term-born children exposed prenatally to a single course of betamethasone 
and those not exposed to sGCs, though schools did report more learning difficulties in those 
exposed (Stutchfield et al. 2013). In addition,  two observational studies reported no differences 
between exposed and non-exposed term-born children in the levels of affective problems at the age 
of 6-10 years (Davis et al. 2013), or in intelligence at 6-11 years (Alexander et al. 2016). Finally, in 
one additional observational study those term-borns exposed to sGCs displayed higher salivary 
cortisol stress reactivity to a standardized psychosocial stress test than their non-exposed term-born 
peers at 6-11 (Alexander et al. 2012) and at 14-18 (Ilg et al. 2018) years of age.    
 
The mixed findings may result from different study designs, differences in the number of sGC 
courses administered, and the use of varying measures of mental health and psychological 
development at ages that vary in developmental stage. Further, only one of these previous studies 
has examined the possible confounding of maternal obesity and common pre-pregnancy and 
pregnancy disorders (Alexander et al. 2016). These disorders often underpin the risk of preterm 
birth (Rosenberg et al. 2005; Goldenberg et al. 2008), and hence co-occur with antenatal sGC 
treatment.  
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In a well-characterized cohort of Finnish women and their children, we examined the association of 
antenatal betamethasone exposure with early childhood mental and behavioral disorders and 
mother-reported psychiatric problems and developmental milestones. We examined if these 
associations varied by whether the children were born preterm or at term. We also took into account 
maternal early pregnancy obesity, gestational and type 1 diabetes, gestational and chronic 
hypertension and pre-eclampsia, and tested if the association of antenatal betamethasone exposure 
with early childhood mental and behavioral disorders and mother-reported psychiatric problems and 
developmental milestones varied by sex, as one of the previous studies in term-born children 
showed that  the effects of sGC treatment on stress reactivity might show sex-specificity (Alexander 
et al. 2012). 
 
 
Method 
 
Participants 
The Prediction and Prevention of Pre-eclampsia and Intrauterine Growth Restriction (PREDO) 
study comprises 4,777 mothers who gave birth to a singleton liveborn child in Finland 2006-2010 
(Girchenko et al. 2017). Recruitment took place at ten study hospitals in Southern/Eastern Finland 
at the first ultrasound screening between 12+0-13+6 weeks+days-of-gestation. The original study 
cohort comprises three subgroups: 969 pregnant women with known clinical risk factors for pre-
eclampsia and IUGR, 110 women with no known risk factors for these conditions, and 3,698 
women who were recruited whether or not they had risk factors for pre-eclampsia and IUGR 
(Girchenko et al. 2017). From the latter group two women have since withdrawn consent. 
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Diagnoses on mental and behavioral disorders from child birth up to December 31st 2016 were 
available from 4,752 children. Of them, 4,708 also had information on antenatal betamethasone 
exposure and other important pregnancy and perinatal characteristics. At the end of the register 
follow-up the children were 6-10 years-of-age (Mean=7.7, standard deviation [SD]=0.8). 
 
Additional information on mother-reported child psychiatric problems and developmental 
milestones were available from a follow-up conducted in 2011-2012. Mother-reported data on child 
psychiatric problems and/or developmental milestones and data on antenatal betamethasone 
exposure and other important pregnancy and perinatal characteristics were available for 2,640 
children at 1.9-5.9 years-of-age (Mean=3.5, SD=0.7). See online Supplementary Fig S1 for the 
sample and attrition. 
 
Compared to the initial sample from whom we missed child disorders or 
betamethasone/pregnancy/perinatal data (N=67), the ones with these data available (N=4,708) were 
born to mothers who 8.7% less often smoked during pregnancy, 9.3% less often had chronic 
hypertension, and 5.8% more often had gestational hypertension; the children themselves were born 
5.8% less often preterm (all p-values<0.04). Compared to the invited non-participants of the 2011-
2012 follow-up (N=1,945), the 2011-2012 follow-up study participants (N=2,640) were born to 
mothers who were 0.7-years-older at delivery, 10.1% more often had a tertiary education, 2.1% less 
often were single, 5.7% more often primiparous, 1.4% less often had chronic hypertension, 5.2% 
less often smoked during pregnancy, had 0.5 kg/m2 lower early pregnancy body mass index (BMI) 
and were 3.3% less often obese (all p-values<0.01).  
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All participating women signed informed consents. The PREDO study protocol was approved by 
the Ethics Committees of the Hospital District of Helsinki and Uusimaa and by the participating 
hospitals.  
 
Exposure to synthetic glucocorticoids  
Information on betamethasone treatment (yes/no) was extracted from medical records and/or the 
Finnish Medical Birth Register (MBR). For a subset of women who were recruited based on their 
risk factor status for pre-eclampsia and IUGR, we had information on the number of courses (N=43; 
Mean=1, SD=0.4, range 0.5-2 courses of 2x12mg per course) and the timing of the exposure (N=45; 
Mean=3.5, SD=3.9, range 0-13 weeks before delivery). 
 
Child Mental and Behavioral Disorders 
We identified diagnoses of child mental and behavioral disorders from the Finnish Hospital 
Discharge Register (HDR) from the child’s birth between 2006-2010 to December 31st, 2016. The 
HDR includes primary and subsidiary diagnoses of all inpatient and outpatient visits (data on both 
visits available since the child’s birth) coded using International Classification of Diseases-10 (ICD-
10) during the study period and is a valid tool for research (Sund 2012). We analyzed those 
disorders which included children in the betamethasone-exposed and non-exposed groups born 
preterm and at term (Table S1); children with no disorders were used as the referent in all analyses ( 
Table S1).  
 
Mother-reported child psychiatric problems 
The Child Behavior Checklist 1½-5 years (CBCL) comprises 99 problem items rated on a scale of 0 
(not true) to 2 (very true or often true) (Achenbach & Rescorla 2000). The CBCL yields total, 
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internalizing, and externalizing problems scores (Achenbach & Rescorla 2000). See online 
Supplementary Text for internalizing and externalizing problems subscales.  
 
Mother-reported child developmental milestones 
The Ages and Stages Questionnaire-3 (ASQ) (Squires et al. 1997) measures age-appropriate 
developmental milestones in five domains (communication, fine motor, gross motor, problem 
solving ability, and personal-social functioning). Six questions in each domain indicate whether the 
child has mastered (‘yes’, 10 points), partly/inconsistently mastered (‘sometimes’, 5 points), or not 
yet mastered the milestone (‘not yet’, 0 points) (Squires et al. 1997). We defined mild 
developmental delay as scores between -1 and -2 SD below the age-appropriate mean, and failure to 
meet the development that is typical for the child’s age as scores -2 SD or more below the age-
appropriate mean for each domain (Squires et al. 1997). The ASQ  is a reliable and valid screening 
tool for determining children in need of further developmental assessment (Kerstjens et al. 2009; 
Filgueiras et al. 2013; Steenis et al. 2015; Charkaluk et al. 2017). 
 
Covariates and moderators 
These included maternal age at delivery (years), parity (primiparous/multiparous), delivery mode 
(vaginal/caesarean section), premature rupture of membranes (yes/no), smoking during pregnancy 
(no/quit or smoked throughout), maternal early pregnancy BMI (kg/m2), chronic and gestational 
hypertension, pre-eclampsia, gestational and type 1 diabetes (all categorized yes/no), weight, length 
and head circumference at birth standardized by sex and gestational age (Pihkala et al. 1989) (SD 
units), gestational age (analyzed both as a continuous covariate and dichotomous [<37/ ≥37 
gestational weeks] moderator), and child’s sex (analyzed both as a covariate and a moderator), 
which were extracted from the MBR, HDR, and/or from medical reports. Maternal alcohol use 
during pregnancy (yes/no), education (primary or secondary/ tertiary) and maternal history of 
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physician-diagnosed asthma (yes/no), as some in this group may be taking corticosteroid inhalers, 
were reported in early pregnancy, and child’s age (months) was reported in the follow-up. For the 
analyses of child mental and behavioral disorders as the outcomes, we also made adjustments for 
maternal any mental disorder diagnosis based on HDR inpatient and outpatient visits (any/no DSM-
III-R/ICD-10 diagnosis of mental/behavioral disorder; inpatient data were available between 1987 
and 2016; outpatient data were available between 1998 and 2016; birth year of the mothers varied 
from 1959 to 1977). For the analyses of mother-reported child outcomes, we made adjustments for 
maternal depressive symptoms during pregnancy (trimester-weighted mean score of bi-weekly 
reports) measured using the Center for Epidemiological Studies Depression Scale (CES-D) (Radloff 
1977), and concurrently to rating the child using the Beck Depression Inventory-II (BDI-II) (Beck 
et al. 1996). 
 
Statistical analysis 
Statistical analyses were conducted by using IBM SPSS Statistics software, version 24 and SAS, 
version 9.4.  
 
Since the PREDO study was not originally designed to study the effects of betamethasone treatment 
on child developmental outcomes, we used propensity score weighing (Austin 2011) to account for 
the differences in baseline characteristics associated with betamethasone treatment (Table 1). We 
determined the propensity score weights by logistic regression to estimate the probability of 
receiving betamethasone treatment conditional on the observed covariates. We then trimmed the 
highest propensity score weights downwards with a 95th percentile cutpoint (Lee et al. 2011). The 
resulting propensity score weights were used in all analyses. Because the sample size differed 
between the child disorders (N=4,708) and mother-reported child outcomes (N=2,640), we 
calculated the propensity score weights separately for these two samples. 
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Using logistic regression analysis, we tested the associations between antenatal betamethasone 
exposure and child main category diagnoses of mental and behavioral disorders (Table S1), and 
multinomial logistic regression to test associations with having just one or two to four co-morbid 
mental and behavioral disorders compared to no disorders. If associations with the main category 
disorders were significant, we specified the associations by analyzing the disorders in the specific 
disorder category (Table S1).  
 
We then tested the associations between antenatal betamethasone exposure and mother-reported 
child total, internalizing, and externalizing problems (converted into SD units) by using generalized 
linear models with Gaussian reference distribution. Associations between antenatal betamethasone 
exposure and mother-reported child developmental milestones (scores >-1SD contrasted with scores 
between -1SD and -2SD and with scores ≤-2SD) were tested by using multinomial logistic 
regression analysis.  
 
Analyses of child disorders as outcomes included the propensity score weights and  child’s sex and 
birth year as covariates, and mother-reported child outcomes propensity score weights andchild’s 
sex and age at follow-up as covariates (model 1). We then added all the other covariates into the 
models, except for maternal mental health (model 2). Further, maternal mental disorder derived 
from HDR was added into the models with child  disorders as outcomes, and maternal depressive 
symptoms during pregnancy and at the time of rating the child outcomes were added into the 
models of mother-reported child outcomes (model 3). To study whether birth length or head 
circumference SD had an effect on the findings, we re-ran models 2-3 by replacing child’s birth 
weight SD score with birth length and head circumference SD scores as covariates. 
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We entered an interaction term ‘betamethasone exposure/non-exposure x preterm/term birth’ into 
the equations to study if the betamethasone associations varied by preterm/term status, and an 
interaction term ‘betamethasone exposure/non-exposure x girl/boy’ into the equations to study if the 
betamethasone associations varied by child’s sex. 
 
 
Results 
 
Table 1 shows that compared to non-exposed children, betamethasone-exposed children had lower 
gestational age, were more often born preterm, had lower weight, length and head circumference at 
birth, had lower birth weight and length SD scores, and were more often born small-for-gestational 
age in weight and length. They were also more often delivered by caesarean section and  born from 
pregnancies complicated by pre-eclampsia, type 1 diabetes, obesity, and premature rupture of 
membranes (Table 1).  
 
Betamethasone exposure and child mental and behavioral disorders 
The prevalence of any mental and behavioral, psychological development, and behavioral and 
emotional disorders, and of two to four co-morbid disorders from the main diagnosis categories 
(Table 2) was significantly higher in the betamethasone-exposed than non-exposed children in 
models including the propensity score weights and all covariates (model 1 adjusted for child’s sex 
and age; model 2 adjusted additionally for maternal BMI, hypertensive and diabetic pregnancy 
disorders, delivery mode, age, education, parity, smoking and alcohol use, asthma, premature 
rupture of membranes, and child’s gestational age and birth weight SD score; and model 3 adjusted 
additionally for maternal mental disorders; Table 2).  
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Of the specific disorders of psychological development and behavioral and emotional disorders, the 
prevalence of speech and language (6.8% vs 2.9%, OR=2.57, 95% CI=1.25 to 5.30, p≤0.05 for 
models including propensity score weights and adjusting for all covariates) and other disorders of 
psychological development (4.3% vs 0.7%, OR=7.26, 95% CI=2.83 to 18.62, p<0.001 for models 
including propensity score weights and adjusting for all covariates) and hyperkinetic disorders 
(6.0% vs 1.4%, OR=4.70, 95% CI=2.11 to 10.49, p<0.02  for models including propensity score 
weights and adjusting for all covariates) were significantly higher in the betamethasone-exposed 
than non-exposed children. 
 
None of these associations were altered when we replaced birth weight SD score with birth length 
and head circumference SD scores (p-values≤0.05 for models including propensity score weights 
and all covariates; data not shown). 
 
The interaction analyses ‘betamethasone-exposure/non-exposure x preterm/term birth’ (all p-
values>0.27) or ‘betamethasone exposure/non-exposure x girl/boy’ did not reveal any significant 
interactions (all p-values>0.07; data not shown). 
 
Betamethasone exposure and mother-reported child outcomes 
Betamethasone-exposure was associated with higher scores on total, internalizing, and externalizing 
problems in models including the propensity score weights and all covariates (models 1-3 in Table 
3). See online Supplementary Table S2 for associations with internalizing and externalizing 
problems subscales. 
 
The prevalence of failing to meet the development that is typical for the child’s age in 
communication, problem solving, and personal social skills was higher in betamethasone-exposed 
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compared to non-exposed children in models including the propensity score weights and child’s sex 
and age (model 1 in Table 4). The association with personal social skills survived when adjusted for 
all covariates, while the association with communication and problem solving did not (models 2-3 
in Table 4). The associations with total, internalizing, and externalizing problems, and with the 
failure to meet the development that is typical for child’s age in personal social skills remained 
unchanged when birth weight SD score was replaced with birth length and head circumference SD 
scores (p-values≤0.03 in models including propensity score weights and all covariates; data not 
shown). 
 
The interaction analyses ‘betamethasone-exposure/non-exposure x preterm/term birth’ did not 
reveal any significant interactions (all p-values>0.12; data not shown). Further, we found one 
significant betamethasone exposure/non-exposure x girl/boy interaction on externalizing problems 
(p=0.04). In boys, betamethasone-exposure was associated with higher externalizing problems 
scores (B=0.66, 95% CI=0.28 to 1.04, p=0.001) while in girls, it was not (p=0.33). 
 
 
Discussion 
 
Our study shows that antenatal exposure to betamethasone may be associated with early childhood 
mental health problems. The prevalence of any mental and behavioral disorder, psychological 
development (specifically speech and language) and behavioral and emotional (specifically 
hyperkinetic) disorders in childhood was higher in the betamethasone-exposed than betamethasone 
non-exposed children. Compared to non-exposed children, the prevalence of co-morbid mental and 
behavioral disorders was also higher in the betamethasone-exposed children. Our study findings 
with mother-reported child outcomes are in alignment: compared to the non-exposed children, 
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betamethasone-exposed children had higher scores on total, internalizing, and externalizing 
problems, and they had a higher prevalence of failing to meet the development that is typical for the 
child’s age in personal social skills. Our findings are thus the first to show that exposure to sGCs is 
associated with child mental health problems that are robust and consistent across the sources of 
information; these harms not only relate to child mental and behavioral disorders but also to 
problems that are sub-threshold.   
 
None of these associations varied significantly between those born preterm and at term. These 
associations, tested in the presence of propensity score weights and adjusted for a number of 
important covariates, including maternal pregnancy and pre-pregnancy conditions, smoking and 
alcohol use, education level, and premature rupture of membranes increasing the risk of preterm 
birth (Rosenberg et al. 2005; Goldenberg et al. 2008) and hence the risk of exposure to antenatal 
sGCs, as well as child’s gestational age, birth weight, length, and head circumference SD score. 
Importantly, the associations were not either explained by maternal mental disorders derived from 
HDR up to the same date as the child’s follow-up end-date or maternal depressive symptoms 
reported during or after pregnancy, which also increase the risk of preterm birth (Jarde et al. 2016) 
and child mental and behavioral disorders (Lahti et al. 2017; Tuovinen et al. 2018). Our findings, 
thus, additionally suggest that in term children, the potential benefits of antenatal sGCs may not 
outweigh the longer-term developmental harms. This observation is important as preterm birth is 
difficult to predict and a large number, in our study almost 50%, of the women administered 
antenatal sGCs, continue to deliver at term. This observation assumes further relevance as antenatal 
sGCs may be administered also in late-preterm deliveries and early term caesarian section deliveries 
as a result of observations of their short-term respiratory benefits (Stutchfield 2005; Kamath-Rayne 
et al. 2016; Saccone & Berghella 2016; The American College of Obstetricians and Gynecologists 
2016; Sweet et al. 2017). Further, even in preterm individuals, antenatal sGCs may have different 
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effects on neurodevelopment depending on individual tissue-sensitivity to sGCs (van der Voorn et 
al. 2015). Individual genetic variations in glucocorticoid sensitivity and exposure to antenatal sGCs 
have been associated with IQ and behavior in young adults born preterm (van der Voorn et al. 
2015). Future studies should further examine the possibility of more tailor-made approaches in sGC 
dosing. 
 
Our study findings disagree with the previous observational studies showing null effects of sGCs on 
affective problems (Davis et al. 2013) and intelligence (Alexander et al. 2016) in term-born 
children. Our findings also disagree with the RCTs which have reported null effects of sGCs on 
child behavior problems (Stutchfield et al. 2013; Asztalos et al. 2014) in term-born children. The 
RCTs have, however, shown harmful neurosensory effects in those exposed to multiple vs. a single 
course of sGCs (Asztalos et al. 2014), and harmful effects on learning in those exposed to a single 
course of sGCs vs. no exposure (Stutchfield et al. 2013). Our findings agree with a small 
observational study combining preterm and term children which found that those exposed to sGCs 
displayed more total psychiatric and inattention problems at age 8 years; These group differences 
were rendered non-significant at the age of 16 years (Khalife et al. 2013). This latter study did not 
examine if the effects varied by preterm/term birth. This precludes direct comparisons of our 
findings with findings of this study. Whether these harmful associations found in our study persist 
as the children age, is a subject of future studies. 
 
As the placenta metabolizes sGCs poorly, they readily cross to the fetal side (Seckl & Meaney 
2004) and easily pass the blood-brain barrier (Damsted et al. 2011), carrying harmful effects on the 
fetal brain development. Glucocorticoids bind to glucocorticoid and mineralocorticoid receptors in 
the brain which are abundant especially in the hippocampus (Reul & De Kloet 1985) and in the 
human fetus they are expressed already at 24 weeks of gestation (Noorlander et al. 2006). This 
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corresponds with the typical timing of the administration of sGCs in clinical practice. Experimental 
animal studies have shown, that sGC administration can lead to a decrease in neuronal proliferation, 
neuronal damage and even neuronal death in the hippocampus (Noorlander et al. 2014). Given the 
importance of the hippocampus in learning, memory, and spatial functioning (Burgess et al. 2002), 
as well as neuroendocrine function (Lupien et al. 2009) and neurobehavioral problems (Geuze et al. 
2005), it is plausible that hippocampus is the key target of sGC-related harms. However in a small 
human study, no hippocampal changes associated with exposure to sGCs were found (Modi et al. 
2001). Another key target may be the cerebellum which undergoes rapid growth after 24 weeks-of-
gestation. The cerebellum is highly dense in glucocorticoid receptors (Pavlík et al. 1984) and plays 
a role in emotion regulation and neurobehavioral development (O’Halloran et al. 2012). Studies 
have found that exposure to sGCs can affect cerebellar development, which subsequently, may 
affect cognitive development (Noguchi 2014) and mental health. 
 
Animal models have also shown other adverse effects of antenatal sGC exposure on offspring brain 
development (Damsted et al. 2011), suggesting that there may be other brain mechanisms through 
which sGCs affect neurobehavioral development as well. In human studies, exposure to sGCs has 
been associated with cortical thinning especially in the rostral anterior cingulate cortex (Davis et al. 
2013), which is also associated with internalizing problems (Boes et al. 2008). In addition, exposure 
to sGCs has been associated with decreased brain surface area and complexity of cortical folding in 
close to or term infants (Modi et al. 2001). Finally, a recent study found that antenatal sGC 
exposure is associated with reduced cord blood neurotrophin-3 (NT-3) in late preterm infants 
(Hodyl et al. 2016). NT-3 mediates neuronal growth, differentiation and synapse formation 
(Conover & Yancopoulos 1997), and thus may provide one mechanism through which sGC 
exposure affects brain development and subsequent mental health. 
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An additional novel finding of this study is that betamethasone appeared to exert sex-specific 
associations with mother-reported externalizing problems. This is of interest as boys in our and in 
other samples display higher scores on these problems, possibly resulting in a higher variance and 
statistical power to detect the associations in boys. Alternatively, this may suggestthat boys may be 
more susceptible to the harmful effects of sGCs. However, a previous observational study showed 
that the association of betamethasone with higher salivary cortisol stress-reactivity was present in 6-
11-year-old girls (Alexander et al. 2012). In a later follow-up of this study, at age 14-18 years, the 
sex-specific effects in cortisol reactivity were no longer present (Ilg et al. 2018). However, this may 
reflect the small sample size, since only 44 of the 209 original study participants participated in the 
follow-up (Ilg et al. 2018). The sex-specific effects of sGC exposure have not been shown in other 
human studies, and findings from animal studies remain mixed (Kapoor et al. 2008). The study by 
Alexander et al. comprised both pre-pubertal and pubertal children  (Alexander et al. 2012) while 
our sample was pre-pubertal. Hence, future studies are warranted to unravel if the sex-specificity of 
the antenatal sCG exposure differs according to the child’s developmental stage.   
 
The strengths of our study include a longitudinal study design and a well-characterized large cohort 
with detailed information on the maternal pregnancy and mother-child perinatal characteristics and 
child developmental outcome data from different sources. Further, follow-up attrition with 
information on mental and behavioral disorders was minimal. A further strength is that the findings 
were in alignment regardless of the source of information lending validity to our findings. A 
limitation of our study is that it was not originally designed to test the effects of antenatal 
betamethasone on child developmental outcomes. Yet, our study was designed to examine risk 
factors for pre-eclampsia and IUGR, which increase the risk for preterm birth (Goldenberg et al. 
2008) and, thus, exposure to antenatal sGC. This resulted in the prevalence of pre-eclampsia in the 
PREDO cohort being markedly higher (4.1% vs 0.8-1.9%) than in the Finnish general population 
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(Girchenko et al. 2017). In addition, compared to the Finnish general population, the PREDO 
mothers had a higher prevalence of early pregnancy obesity (14.0% vs 11.5%), gestational 
hypertension (4.2% vs 3.1%) and caesarean section deliveries (17.2% vs 15.8-16.2%), were older at 
delivery (31.5 vs 29.4-29.5 years), more often multiparous 61.3% vs 57.9-59.0%), and less often 
smoked throughout pregnancy (5.0% vs 11.1-11.4%) (Girchenko et al. 2017). This may limit the 
generalizability of our findings. However, the gestational age and birth weight of the children in the 
cohort corresponded with the national average (Girchenko et al. 2017). Further, while our sample 
size was large and the prevalence of pre-eclampsia high, the number of children exposed to 
betamethasone prenatally was still relatively small. The number of children with mental and 
behavioral disorders was also relatively small which precluded studying rarer specific disorders. 
Also, our observational study design precludes causal inferences. Randomized double-blinded 
controlled experimental clinical trials comparing the outcomes of antenatal betamethasone exposure 
on child outcomes in representative study samples are needed to make causal inferences. Finally, 
we had information on the dose and timing of the antenatal betamethasone treatment only for a 
small number of study participants, precluding tests of dose- or timing-dependent effects. However, 
repeated betamethasone courses were not recommended during the time our cohort was born 
(Uotila et al. 2011). In the subsample of our study whom dosage and timing information was 
available, only one mother had received two courses of betamethasone. 
 
Our findings show that the term-born sGC-exposed children have similar problems in mental health 
than the sGC-exposed children who are born preterm. At the moment, children born preterm are 
followed up regardless of whether they were exposed to sGCs or not, but there is no systematic 
clinical follow-up of children exposed to sGCs who end up being born at term. These findings thus 
carry a public health message suggesting the need to extend clinical follow-up of child mental 
health beyond the preterm group to the group exposed to antenatal sGCs and born at term. 
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Table legends 
 
 
Table 1. Characteristics of the sample according to antenatal exposure to betamethasone. 
Characteristics are shown for the sample with data available on child’s mental and behavioral 
disorder diagnoses from the child’s birth in 2006-2010 to December 31st 2016 and for the sample 
with mother-reported child psychiatric problems and developmental milestones data available at the 
child age of 1.9 to 5.9 years.   
 
Table 2. The associations between antenatal betamethasone exposure and child main category 
diagnoses of mental and behavioral disorders according to the International Classification of 
Diseases-10. 
 
Table 3. The associations between antenatal betamethasone exposure and mother-reported 
psychiatric problems of the child. 
 
Table 4. The associations between antenatal betamethasone exposure and mother-reported 
developmental milestones of the child. 
Supplement 1. 
 
 
Child Behavior Checklist subscale analyses 
 
Methods 
 
The Child Behavior Checklist 1½-5 years (CBCL) yields seven syndrome (emotionally reactive, 
anxious/depressed, somatic complaints, withdrawn, sleep problems, attention problems, and 
aggressive behavior) and five Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV)-
oriented scales DSM-IV-oriented (affective, anxiety, pervasive developmental, attention-
deficit/hyperactivity [ADHD], and oppositional defiant problems) subscales in addition to total, 
internalizing, and externalizing psychiatric problems scales (Achenbach & Rescorla 2000). 
 
 
Statistical analyses 
 
Associations between antenatal betamethasone exposure and CBCL syndrome and DSM-IV-
oriented scales were tested by using generalized linear models with Gaussian reference distribution  
Raw scores were used in all analyses with the syndrome and DSM-IV-oriented scales, as 
recommended in the manual for the CBCL (Achenbach & Rescorla 2000). The variables were 
square-root transformed to obtain normality and converted into standard deviation (SD) units with a 
mean of 0 and SD of 1 to provide comparable effect size estimates. We used propensity score 
weighing (Austin 2011) in all analyses to account for observed covariates that were associated with 
betamethasone treatment. 
 All analyses included the propensity score weights and were first adjusted for child’s sex and age at 
follow-up (model 1), and then for maternal early pregnancy BMI, hypertensive and diabetic 
pregnancy and pre-pregnancy disorders, delivery mode, mother’s age at delivery, education, parity, 
premature rupture of membranes, smoking and alcohol use during pregnancy, past or present 
physician-diagnosed asthma, and child’s birth weight SD score and gestational age (model 2). In the 
last model we made adjustments for maternal depressive symptoms during pregnancy and at the 
time of rating the child (model 3). 
 
Finally, we entered an interaction term ‘betamethasone exposure/non-exposure x preterm/term 
birth’ into the equations to study if the betamethasone effects varied by preterm/term status, and an 
interaction term ‘betamethasone exposure/non-exposure x girl/boy’ into the equations to study if the 
betamethasone effects varied by child’s sex. 
 
 
Results 
 
Betamethasone-exposure was associated with higher scores on emotionally reactive, withdrawn, 
attention problems, aggressive behavior, anxiety problems, pervasive developmental problems and 
ADHD problems scales (see Table S2, available online). These differences persisted across the 
different adjustment models including the propensity score weights, except for aggressive problems 
and anxiety problems which attenuated to nonsignificant in model 3 and model 2, respectively (see 
Table S2, available online). 
 
The interaction analyses ‘betamethasone-exposure/non-exposure x preterm/term birth’ revealed 
three significant interactions: These were found on the withdrawn problems, sleep problems, and 
anxiety problems scales (p-values for interaction=0.03, 0.008, and 0.007, respectively; p-
values>0.06 for the other interactions in the analyses of the other psychiatric problems scales). Sub-
analyses, separately in those born preterm and term revealed that in the preterm group, exposure to 
betamethasone was associated with lower scores on sleep problems than (B=-0.40, 95% CI=-0.79 to 
-0.01, p=0.045), however in the term group the exposed and non-exposed children did not differ 
significantly (p=0.10). Yet, in the term group, betamethasone-exposure was associated with higher 
scores on withdrawn and anxiety problems (B=0.50, 95% CI=0.16 to 0.83, p=0.004; B=0.50, 95% 
CI=0.17 to 0.84, p=0.004, respectively), while among children born preterm, the exposed and non-
exposed groups did not differ significantly (p-values>0.30). 
 
In the interaction analyses with ‘betamethasone exposure vs. non-exposure x sex’, we found one 
significant interaction; for aggressive behavior (p=0.04 for interaction) (p-values>0.20 for 
interactions in the analyses of the other psychiatric problems scales). Analyses in boys and girls 
separately showed that in boys, betamethasone-exposure was associated with higher scores on 
aggressive behavior (B=0.61, 95% CI=0.24 to 0.98, p=0.001); exposed and non-exposed girls did 
not differ on this scale (p-value=0.54). 
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Supplementary Table S1. Number and percentage of diagnoses of mental and behavioral disorders 
according to the International Classification of Diseases-10 in the betamethasone-exposed and non-exposed 
groups in the analytic sample. 
International 
Classification of 
Disorders, tenth revision 
(ICD-10) diagnoses 
All Term Preterm 
Betametha
sone-
exposed 
(N=117) 
Betametha
sone non-
exposed 
(N=4,591) 
Betametha
sone-
exposed 
(N=56) 
Betametha
sone non-
exposed 
(N=4,465) 
Betametha
sone-
exposed 
(N=61) 
Betametha
sone non-
exposed 
(N=126) 
N (%) N (%) N (%) N (%) N (%) N (%) 
Any mental and 
behavioral disorder (F00-
F99) 
24 (20.5) 386 (8.4) 10 (17.9) 373 (8.4) 14 (23.0) 13 (10.3) 
ICD-10 main diagnosis 
categories       
  Schizophrenia, 
schizotypal and delusional 
disorders (F20-F29) 
0 (0.0) 2 (0.0) 0 (0.0) 2 (0.0) 0 (0.0) 0 (0.0) 
  Mood disorders (F30-
F39) 0 (0.0) 4 (0.1) 0 (0.0) 4 (0.1) 0 (0.0) 0 (0.0) 
  Neurotic, stress-related 
and somatoform disorders 
(F40-F48) 
0 (0.0) 12 (0.3) 0 (0.0) 12 (0.3) 0 (0.0) 0 (0.0) 
  Behavioural syndromes 
associated with 
physiological 
disturbances and physical 
factors (F50-F59) 
2 (1.7) 30 (0.7) 2 (3.6) 30 (0.7) 0 (0.0) 0 (0.0) 
  Disorders of adult 
personality and behavior 
(F60-F69) 
0 (0.0) 2 (0.0) 0 (0.0) 2 (0.0) 0 (0.0) 0 (0.0) 
  Mental retardation (F70-
F79) 3 (2.6) 16 (0.3) 0 (0.0) 16 (0.4) 3 (4.9) 0 (0.0) 
  Disorders of 
psychological 
development (F80-F89) 
19 (16.2) 238 (5.2) 9 (16.1) 231 (5.2) 10 (16.4) 7 (5.6) 
  Behavioral and 
emotional disorders with 
onset usually occuring in 
childhood and 
adolescence (F90-F98) 
14 (12.0) 184 (4.0) 5 (8.9) 175 (3.9) 9 (14.8) 9 (7.1) 
  Unspecified mental 
disorder (F99) 0 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) 0 (0.0) 0 (0.0) 
       
Number of main category 
diagnoses       
  0 93 (79.5) 4,205 (91.6) 46 (82.1) 4,092 (91.6) 47 (77.0) 113 (89.7) 
  1 12 (10.3) 293 (6.4) 5 (8.9) 283 (6.3) 7 (11.5) 10 (7.9) 
  2-4 12 (10.3) 93 (2.0) 5 (8.9) 90 (2.0) 7 (11.5) 3 (2.4) 
Specific diagnoses       
  Nonorganic sleep 
disorders (F51) 1 (0.9) 20 (0.4) 1 (1.8) 20 (0.4) 0 (0.0) 0 (0.0) 
  Specific developmental 
disorders of speech and 
language (F80) 
8 (6.8) 134 (2.9) 2 (3.6) 130 (2.9) 6 (9.8) 4 (3.2) 
  Specific developmental 
disorders of scholastic 
skills (F81) 
2 (1.7) 18 (0.4) 2 (3.6) 17 (0.4) 0 (0.0) 1 (0.8) 
  Specific developmental 
disorder of motor function 
(F82) 
3 (2.6) 72 (1.6) 0 (0.0) 70 (1.6) 3 (4.9) 2 (1.6) 
  Mixed specific 
developmental disorders 
(F83) 
3 (2.6) 49 (1.1) 0 (0.0) 47 (1.1) 3 (4.9) 2 (1.6) 
  Pervasive developmental 
disorders (F84) 2 (1.7) 30 (0.7) 1 (1.8) 29 (0.6) 1 (1.6) 1 (0.8) 
  Other disorders of 
psychological 
development (F88) 
5 (4.3) 34 (0.7) 4 (7.1) 33 (0.7) 1 (1.6) 1 (0.8) 
  Unspecified disorder of 
psychological 
development (F89) 
2 (1.7) 5 (0.1) 2 (3.6) 5 (0.1) 0 (0.0) 0 (0.0) 
  Hyperkinetic disorders 
(F90) 7 (6.0) 62 (1.4) 3 (5.4) 60 (1.3) 4 (6.6) 2 (1.6) 
  Disorders of social 
functioning with onset 
specific to childhood and 
adolescence (F94) 
1 (0.9) 11 (0.2) 1 (1.8) 11 (0.2) 0 (0.0) 0 (0.0) 
  Other behavioural and 
emotional disorders with 
onset usually occurring in 
childhood and 
adolescence (F98) 
6 (5.1) 82 (1.8) 1 (1.8) 77 (1.7) 5 (8.2) 5 (4.0) 
  Conduct disorders (F63, 
F90.1, F91-F92) 2 (1.7) 27 (0.6) 0 (0.0) 25 (0.6) 2 (3.3) 2 (1.6) 
  Emotional disorders 
(F30-F39, F40-49, F92-
F93) 
1 (0.9) 67 (1.5) 0 (0.0) 64 (1.4) 1 (1.6) 3 (2.4) 
 
Table 1. Characteristics of the sample according to antenatal exposure to betamethasone. Characteristics are shown for the sample with data 
available on child’s mental and behavioral disorder diagnoses from the child’s birth in 2006-2010 to December 31st 2016 and for the sample with 
mother-reported child psychiatric problems and developmental milestones data available at the child age of 1.9 to 5.9 years. 
 Sample with data available on mental and behavioral disorders of the child 
Sample with data available on mother-reported psychiatric 
proglems and developmental milestones of the child 
  
Betamethasone-
exposed 
(N=117) 
Betamethasone 
non-exposed 
(N=4,591) 
  
Betamethasone-
exposed 
(N=61) 
Betamethasone 
non-exposed 
(N=2,579) 
 
 N Mean/N SD/% Mean/N SD/% p N Mean/N SD/% Mean/N SD/% p 
Maternal characteristics             
Age at delivery 4,708 32.3 5.1 31.5 4.9 0.07 2,640 32.3 5.7 31.8 4.6 0.44 
Education (tertiary) 4,334 62 54.9 2,496 59.1 0.36 2,637 35 57.4 1,615 62.7 0.40 
Hypertensive disorders             
  Chronic hypertension 
(yes) 4,708 7  6.0 184 4.0 0.29 2,640 6 9.8 88 3.4 0.007 
  Pre-eclampsia (yes) 4,708 21 17.9 188 4.1 <0.001 2,640 12 19.7 106 4.1 <0.001 
  Gestational 
hypertension (yes) 4,708 11 9.4 261 5.7 0.09 2,640 6 9.8 138 5.4 0.13 
Diabetic disorders             
  Type 1 diabetes (yes) 4,708 6 5.1 21 0.5 <0.001 2,640 3 4.9 10 0.4 <0.001 
  Gestational diabetes 
(yes) 4,708 18 15.4 521 11.3 0.18 2,640 10 16.4 276 10.7 0.16 
Early pregnancy Body 
Mass Index (BMI; 
kg/m2) 
4,708 26.0 6.3 24.5 5.0 0.01 2,640 25.9 6.6 24.3 4.8 0.06 
Early pregnancy obesity 
(BMI ≥ 30 kg/m2; yes) 4,708 27 23.1 634 13.8 0.004 2,640 11 18.0 319 12.4 0.19 
History of physician-
diagnosed asthma (yes) 3,411 8 9.0 259 7.8 0.68 2,292 5 9.1 176 7.9 0.74 
Smoking during 
pregnancy (yes) 4,690 9 7.8 388 8.5 0.78 2,636 5 8.2 162 6.3 0.55 
Alcohol use during 
pregnancy (yes) 3,517 13 14.3 568 16.6 0.56 2,368 9 16.7 390 16.9 0.97 
Delivery mode 
(caesarean section) 4,708 50 42.7 778 16.9 <0.001 2,640 25 41.0 430 16.7 <0.001 
Premature rupture of 
membranes (yes) 4,708 22 18.8 75 1.6 <0.001 2,640 6 9.8 44 1.7 <0.001 
Parity (primiparous) 4,708 49 41.9 1,771 38.6 0.47 2,640 28 45.9 1,063 41.2 0.46 
Any mental and 
behavioral disorder 
according to ICD-9 or 
ICD-10 
4,708 22 18.8 763 16.6 0.53       
Depressive symptoms 
during pregnancy 
(trimester weighted 
mean score) 
      2,333 13.8 7.4 11.3 6.3 0.006 
Depressive symptoms at 
child’s mean age of 3.5 
years (sum score) 
      2,557 7.9 8.5 6.4 6.2 0.16 
Child characteristics             
Sex (boy) 4,708 59 50.4 2,396 52.2 0.71 2,640 26 42.6 1,320 51.2 0.19 
Age at the end of 
register follow-up 
(years) 
4,708 8.0 0.9 7.7 0.8 <0.001       
Age at mother-reported 
developmental outcomes 
(years) 
      2,640 3.6 0.7 3.5 0.7 0.08 
Gestational age (weeks) 4,708 36.2 3.9 40.0 1.4 <0.001 2,640 36.7 3.9 40.0 1.4 <0.001 
Preterm birth (birth <37 
weeks of gestation) 4,708 61 52.1 126 2.7 <0.001 2,640 28 45.9 75 2.9 <0.001 
Birth weight (grams) 4,708 2,664 952 3,554 489 <0.001 2,640 2,853 962 3,545 485 <0.001 
Birth weight 
standardized by sex and 
gestational age 
according to Finnish 
growth charts (SD units) 
4,708 -0.7 1.2 -0.0 1.0 <0.001 2,640 -0.4 1.2 -0.1 1.0 0.004 
Small-for-gestational 
age in birth weight 4,708 15 12.8 90 2.0 <0.001 2,640 4 6.6 53 2.1 0.02 
Birth length (cm) 4,708 46.0 5.1 50.3 2.1 <0.001 2,640 46.7 5.1 50.2 2.1 <0.001 
Birth length 
standardized by sex and 
gestational age 
according to Finnish 
growth charts (SD units) 
4,708 -0.6 1.5 -0.1 1.0 0.001 2,640 -0.5 1.4 -0.1 1.0 0.07 
Small-for-gestational 
age in birth length 4,708 19 16.2 157 3.4 <0.001 2,640 8 13.1 93 3.6 <0.001 
Head circumference at 
birth (cm) 4,708 32.7 3.1 35.1 1.5 <0.001 2,640 33.2 3.2 35.1 1.5 <0.001 
Head circumference at 
birth standardized by sex 
and gestational age 
according to Finnish 
growth charts (SD units) 
4,708 -0.1 1.3 -0.0 1.0 0.41 2,640 -0.0 1.3 -0.1 1.0 0.80 
Small-for-gestational 
age in birth head 
circumference 
4,708 4 3.4 88 1.9 0.25 2,640 3 4.9 55 2.1 0.14 
The differences between the betamethasone-exposed and non-exposed groups are determined using t-tests for continuous variables and chi-
squared test for categorized variables. 
 

Table 2. The associations between antenatal betamethasone exposure and child main category diagnoses of mental and behavioral disorders according 
to the International Classification of Diseases-10. 
International Classification of 
Disorders, tenth revision (ICD-10) 
diagnoses 
Betametha
sone-
exposed 
Betametha
sone non-
exposed 
Model 1  Model 2  Model 3  
N % N % Odds Ratio 
95% 
CI p 
Odds 
Ratio 
95% 
CI p 
Odds 
Ratio 
95% 
CI p 
Any mental and behavioral disorder (F00-
F99) 24 20.5 386 8.4 2.76 
1.76, 
4.32 <0.001 2.56 
1.50, 
4.38 <0.001 2.58 
1.50, 
4.42 <0.001 
ICD-10 main diagnosis categories              
Disorders of psychological development 
(F80-F89) 19 16.2 238 5.2 3.61 
2.19, 
5.95 <0.001 3.59 
1.96, 
6.59 <0.001 3.57 
1.94, 
6.59 <0.001 
Behavioral and emotional disorders with 
onset usually occurring in childhood and 
adolescence (F90-F98) 
14 12.0 184 4.0 3.29 1.86, 5.82 <0.001 2.61 
1.28, 
5.31 0.008 2.66 
1.30, 
5.46 0.007 
Number of co-morbid ICD-10 main 
category diagnoses              
1 12 10.3 293 6.4 1.80 0.99, 3.25 0.05 1.66 
0.14, 
1.10 0.16 1.67 
0.82, 
3.41 0.16 
2-4 12 10.3 93 2.0 6.04 3.25, 11.27 <0.001 4.31 
1.82, 
10.19 <0.001 4.57 
1.91, 
10.95 <0.001 
Only disorders which included children in the betamethasone-exposed and non-exposed groups born preterm and at term were included in the 
analyses. In the analyses with the number of co-morbid ICD-10 main category diagnoses, the group with no mental and behavioral disorders was 
used as referent. 
All models include propensity score weights. 
Model 1: adjusted for child sex and birth year. 
Model 2: adjusted for model 1 + maternal early pregnancy body mass index (kg/m2), hypertensive (gestational hypertension, pre-eclampsia, 
chronic hypertension) and diabetic (gestational diabetes, type 1 diabetes) pregnancy and pre-pregnancy disorders, delivery mode 
(vaginal/caesarean section), premature rupture of membranes (yes/no), mother’s age (years), education (upper/lower tertiary/other), parity 
(primiparous/multiparous), maternal smoking during pregnancy (no/quit or smoked throughout), maternal alcohol use during pregnancy (yes/no), 
maternal history of physician-diagnosed asthma (yes/no), child’s gestational age (weeks), birth weight standardized by sex and gestational age 
according to Finnish growth charts(21) (SD units). 
Model 3: adjusted for model 2 + maternal mental and behavioral disorder (any diagnosis/no diagnosis). 
 
Supplementary Table S2. The associations between antenatal betamethasone exposure and mother-reported 
child internalizing and externalizing psychiatric problems subscales. 
 Model 1  Model 2  Model 3  
Psychiatric problems 
subscales 
Mean difference 
between the 
exposed and non- 
exposed group in 
standard 
deviation units 
(95% CI) 
(N=2,581) 
p 
Mean difference 
between the 
exposed and non- 
exposed group in 
standard 
deviation units 
(95% CI) 
(N=2,581) 
p 
Mean difference 
between the 
exposed and non- 
exposed group in 
standard 
deviation units 
(95% CI) 
(N=2,257) 
P 
Syndrome scales       
  Emotionally Reactive 0.27(0.02, 0.52) 0.03 0.26(0.00, 0.52) 0.049 0.28(0.02, 0.55) 0.04 
  Anxious/ Depressed 0.24(-0.01, 0.49) 0.06 0.17(-0.09, 0.43) 0.20 0.17(-0.10, 0.45) 0.21 
  Somatic Complaints 0.16(-0.09, 0.41) 0.20 0.09(-0.17, 0.35) 0.52 0.05(-0.22, 0.32) 0.70 
  Withdrawn 0.36(0.12, 0.61) 0.004 0.39(0.13, 0.65) 0.003 0.42(0.15, 0.69) 0.002 
  Sleep Problems 0.11(-0.14, 0.36) 0.39 0.09(-0.17, 0.35) 0.50 0.01(-0.27, 0.28) 0.95 
  Attention Problems 0.29(0.04, 0.53) 0.02 0.33(0.07, 0.58) 0.01 0.32(0.05, 0.59) 0.02 
Diagnostic and Statistical 
Manual of Mental 
Disorders-IV-oriented 
scales 
      
  Aggressive Behavior 0.32(0.08, 0.57) 0.01 0.28(0.02, 0.54) 0.04 0.21(-0.06, 0.47) 0.12 
  Affective Problems 0.18(-0.07, 0.43) 0.15 0.12(-0.15, 0.38) 0.38 0.08(-0.19, 0.35) 0.55 
  Anxiety Problems 0.29(0.04, 0.53) 0.02 0.24(-0.02, 0.50) 0.07 0.23(-0.04, 0.50) 0.10 
  Pervasive 
Developmental Problems 0.42(0.17, 0.66) 0.001 0.45(0.19, 0.71) 0.001 0.47(0.21, 0.74) <0.001 
  Attention Deficit 
Hyperactivity Disorder 
Problems 
0.41(0.16, 0.65) 0.001 0.40(0.14, 0.66) 0.002 0.33(0.06, 0.60) 0.02 
  Oppositional Defiant 
Problems 0.20(-0.05, 0.45) 0.11 0.15(-0.11, 0.41) 0.27 0.11(-0.16, 0.38) 0.41 
All models include propensity score weights. 
Model 1: adjusted for child sex (boy/girl) and age (months) 
Model 2: model 1 + maternal early pregnancy body mass index (kg/m2), hypertensive (gestational hypertension, pre-eclampsia, chronic 
hypertension) and diabetic (gestational diabetes, type 1 diabetes) pregnancy and pre-pregnancy disorders, delivery mode 
(vaginal/caesarian section), mother’s age (years), education (tertiary/other), parity (primiparous/multiparous), premature rupture of 
membranes (yes/no), maternal smoking during pregnancy (no/quit or smoked throughout), maternal alcohol use during pregnancy 
(yes/no), maternal history of physician-diagnosed asthma (yes/no), child’s gestational age (weeks), birth weight standardized by sex 
and gestational age according to Finnish growth charts1 (SD units). 
Model 3: model 2 + trimester-weighted mean score of maternal depressive symptoms during pregnancy and maternal depressive 
symptoms at the time of rating the child neurobehavior. 
 
Table 3. The associations between antenatal betamethasone exposure and mother-reported psychiatric problems of the child. 
 Model 1 (N=2,581)  Model 2 (N=2,581)  Model 3 (N=2,257)  
Psychiatric problems 
Mean 
difference 
between 
the 
exposed 
and non-
exposed 
group in 
SD units 
95% CI p 
Mean 
difference 
between 
the 
exposed 
and non-
exposed 
group in 
SD units 
95% CI p 
Mean 
difference 
between 
the 
exposed 
and non-
exposed 
group in 
SD units 
95% CI p 
Total Problems 0.39 0.15, 0.64 0.002 0.35 0.09, 0.61 0.008 0.31 0.05, 0.56 0.02 
Internalizing Problems 0.33 0.09, 0.58 0.008 0.29 0.03, 0.55 0.03 0.28 0.03, 0.54 0.03 
Externalizing Problems 0.38 0.13, 0.62 0.003 0.34 0.08, 0.60 0.01 0.29 0.03, 0.55 0.03 
All models include propensity score weights. 
Model 1: adjusted for child sex (boy/girl) and age (months) 
Model 2: model 1 + maternal early pregnancy body mass index (kg/m2), hypertensive (gestational hypertension, pre-eclampsia, chronic 
hypertension) and gestational (gestational diabetes, type 1 diabetes) pregnancy and pre-pregnancy disorders, delivery mode 
(vaginal/caesarean section), mother’s age (years), education (tertiary/other), parity (primiparous vs. multiparous), premature rupture of 
membranes (yes/no), maternal smoking during pregnancy (no/quit or smoked throughout), maternal alcohol use during pregnancy 
(yes/no), maternal history of physician-diagnosed asthma (yes/no), child’s gestational age (weeks), birth weight standardized by sex 
and gestational age according to Finnish growth charts (Pihkala et al. 1989) (SD units). 
Model 3: model 2 + trimester-weighted mean score of maternal depressive symptoms during pregnancy and maternal depressive 
symptoms at the time of rating the child behavior. 
Table 4. The associations between antenatal betamethasone exposure and mother-reported developmental milestones of the child. 
 No developmental delay (>-1SD as reference group) vs. 
Developmental 
milestones domains 
Mild developmental delay (-2SD > - ≤ -1SD) Fails to meet development typical for child’s age (≤ -2SD) 
Betametha
sone-
exposed 
Betametha
sone non-
exposed 
Odds 
Ratio 95% CI p 
Betametha
sone-
exposed 
Betametha
sone non-
exposed 
Odds 
Ratio 95% CI p 
N % N % N % N  % 
Communication 
skills               
  Model 1 (N=2,470) 4 6.6 129 5.0 1.54 0.56, 4.21 0.40 5 8.2 96 3.7 2.64 1.06, 6.56 0.04 
  Model 2 (N=2,470) 4 6.6 129 5.0 1.26 0.42, 3.79 0.68 5 8.2 96 3.7 1.69 0.57, 5.04 0.35 
  Model 3 (N=2,146) 4 7.8 115 5.2 1.28 0.41, 4.00 0.68 5 9.8 90 4.1 1.63 0.54, 4.94 0.38 
Fine motor skills               
  Model 1 (N=2,455) 6 9.8 208 8.1 1.44 0.61, 3.39 0.40 4 6.6 117 4.5 1.75 0.64, 4.81 0.28 
  Model 2 (N=2,455) 6 9.8 208 8.1 1.08 0.42, 2.76 0.88 4 6.6 117 4.5 1.27 0.40, 4.03 0.69 
  Model 3 (N=2,139) 5 9.8 181 8.2 1.15 0.42, 3.17 0.79 3 5.9 109 4.9 0.99 0.27, 3.72 0.99 
Gross motor skills               
  Model 1 (N=2,469) 4 6.6 177 6.9 1.01 0.38, 2.74 0.98 5 8.8 128 5.0 1.77 0.71, 4.42 0.22 
  Model 2 (N=2,469) 4 6.6 177 6.9 1.00 0.34, 2.92 1.00 5 8.8 128 5.0 0.69 0.22, 2.20 0.53 
  Model 3 (N=2,144) 4 7.8 151 6.8 1.11 0.37, 3.31 0.85 4 7.8 112 5.0 0.68 0.19, 2.40 0.54 
Problem solving 
skills               
  Model 1 (N=2,447) 5 8.2 159 6.2 1.69 0.68, 4.18 0.26 8 13.1 113 4.4 3.74 1.76, 7.94 <0.001 
  Model 2 (N=2,447) 5 8.2 159 6.2 1.61 0.60, 4.33 0.34 8 13.1 113 4.4 3.24 1.37, 7.69 0.008 
  Model 3 (N=2,133) 5 9.8 142 6.4 1.67 0.61, 4.52 0.32 7 13.7 103 4.6 2.45 0.93, 6.46 0.07 
Personal social 
skills          
     
  Model 1 (N=2,479) 6 9.8 225 8.7 1.44 0.62, 3.34 0.39 6 9.8 92 3.6 3.70 1.56, 8.81 0.003 
  Model 2 (N=2,479) 6 9.8 225 8.7 1.13 0.45, 2.83 0.80 6 9.8 92 3.6 3.56 1.32, 9.58 0.01 
  Model 3 (N=2,152) 6 11.8 197 8.9 1.43 0.56, 3.64 0.45 6 11.8 87 3.9 3.76 1.35, 10.43 0.01 
All models include propensity score weights. 
Model 1: adjusted for child sex (boy/girl) and age (months) 
Model 2: model 1 + maternal early pregnancy body mass index (kg/m2), hypertensive (gestational hypertension, pre-eclampsia, chronic hypertension) and 
gestational (gestational diabetes, type 1 diabetes) pregnancy and pre-pregnancy disorders, delivery mode (vaginal/caesarean section), mother’s age (years), 
education (tertiary/other), parity (primiparous vs. multiparous), premature rupture of membranes (yes/no), maternal smoking during pregnancy (no/quit or 
smoked throughout), maternal alcohol use during pregnancy (yes/no), maternal history of physician-diagnosed asthma (yes/no), child’s gestational age 
(weeks), birth weight standardized by sex and gestational age according to Finnish growth charts (Pihkala et al. 1989) (SD units). 
Model 3: model 2 + trimester-weighted mean score of maternal depressive symptoms during pregnancy and maternal depressive symptoms at the time of 
rating the child development. 
 
